"Endocr Metab Immune Disord Drug Targets"[jour] - Search Results

Year	Number of Results
2006	43
2007	32
2008	35
2009	31
2010	39
2011	32
2012	40
2013	41
2014	39
2015	45
2016	39
2017	39
2018	79
2019	139
2020	172
2021	247
2022	140
2023	204
2024	220
2025	241
2026	1

1

Identification of Senescence- and Inflammation-Related Genes and Immune Microenvironment Characterization in Intracranial Aneurysms.

Li X, Li Y, Zhang L, Mao J, Li B. Li X, et al. Endocr Metab Immune Disord Drug Targets. 2026 Jan 2. doi: 10.2174/0118715303420035251023051847. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2026. PMID: 41487007

2

A Case Report of Anti-GAD65 Antibody-Positive Autoimmune Encephalitis Associated with Diabetes.

Xuan X, Meng L, Chen L, Xie X, Liang X, Qin Y. Xuan X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Dec 4. doi: 10.2174/0118715303405229251028051625. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41355548

3

Comprehensive Review on the Protective Effects of Lycium barbarum Polysaccharide on Neurodegenerative Diseases.

Lu Q, Di X, Guo X. Lu Q, et al. Endocr Metab Immune Disord Drug Targets. 2025 Dec 4. doi: 10.2174/0118715303393082251027072838. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41355547

4

Integrative Multi-Omics Deciphering of Gu Shu Kang Granules: A Comprehensive Systems Biology Approach to Unraveling Molecular Mechanisms in Sarcopenia-Osteoporosis Intervention.

Cui X, Yu Z, Wang D, Liu Y, Wang W, Teng H, Yu M, Wang S, Liu H, Wei W. Cui X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Nov 26. doi: 10.2174/0118715303448084251113101628. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41327624

5

Role of the lncRNA MALAT1/miR-1 Pathway in Mouse Myocardial Ischemia-Reperfusion Injury.

Liu J, Zhang B, Li J, Chen Z, Li Y. Liu J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Nov 24. doi: 10.2174/0118715303439119251106075344. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41293924

6

17β-Estradiol Improves Liver Function in T2DMNAFLD Mice via PGC-1α/ERRα Axis Activation While Preserving Cholestatic Safety.

Xu W, Ni Q, Yang Q, Lin Q. Xu W, et al. Endocr Metab Immune Disord Drug Targets. 2025 Nov 24. doi: 10.2174/0118715303434124251112064139. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41293923

7

Association Between Irritable Bowel Syndrome and Hypothyroidism: Insights from Large-Scale Population-Based Studies.

Wu J, Liu Z, Liu L, Liu Q, Sun S, Li H, Li F, Zhou M, Song Y. Wu J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Nov 24. doi: 10.2174/0118715303390590250928210823. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41293922

8

LGI1 Antibody-Associated Encephalitis Complicated with Sjögren's Syndrome and Acute Cerebral Infarction: A Case Report and Literature Review.

Jiang D, Lian Y, Zhan X, Wang J, Xu P, Bi Y. Jiang D, et al. Endocr Metab Immune Disord Drug Targets. 2025 Nov 20. doi: 10.2174/0118715303410062250729095927. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41268826

9

Heterogeneous Hemostatic Disorder Associated with IgA Monoclonal Gammopathy: A Case Series.

Huang CW, Lai GM, Lin CY, Shih YH, Lin HY, Shen MC. Huang CW, et al. Endocr Metab Immune Disord Drug Targets. 2025 Nov 3. doi: 10.2174/0118715303398150251012142255. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41185500

10

Bioinformatics-based Mechanisms of Lipid Metabolism and Endoplasmic Reticulum Stress in Coronary Artery Disease.

Ye L, Ruan H, Chen Q, Chen Y, Wang R, Zhou J, Wang J, He M, Wang K, Huang Y, Wang F. Ye L, et al. Endocr Metab Immune Disord Drug Targets. 2025 Nov 3. doi: 10.2174/0118715303432896251016035431. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41185499

11

Causal Links Between Antibody-Mediated Immune Responses and Pancreatic Cancer Risk.

Zou X, Feng Y, Liu P, Zhang L, Shen J. Zou X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Nov 3. doi: 10.2174/0118715303396420251007140802. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41185498

12

Genetic Causal Association between Treg Subtypes and Acute Respiratory Distress Syndrome: A Mendelian Randomization Study.

Xu H, Li L, Zheng Z, Dong L. Xu H, et al. Endocr Metab Immune Disord Drug Targets. 2025 Nov 3. doi: 10.2174/0118715303399055251010101650. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41185497

13

A Predictive Model for Anemia and Coronary Heart Disease Based on Bidirectional Two-Sample Mendelian Randomization and Machine Learning.

Zhang Y, Fan S, Ma P, Xia Y, Hu Z. Zhang Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 27. doi: 10.2174/0118715303427508251007080833. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41163278

14

Living with PCOS: A Narrative of Its Biology, Diagnosis, and Evolving Treatment.

Shams S, Jawaid S, Rai N, Kala K, Choudhary A, Neelofar N, Anwar F. Shams S, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 27. doi: 10.2174/0118715303390700251003050039. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41163277

15

Exploring In Vivo Anti-Diabetic Potential of 2,3 and 2,6-dichloroindolinone: Biochemical and Histological Evidences.

Rauf A, Alam W, Khan M, Al-Otaibi JS, Pirzada AS, Khan H. Rauf A, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 27. doi: 10.2174/0118715303411204251022055822. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41163276

16

Metformin Alone and in Combinations Alter the Methylation Patterns of ABCG1 and TXNIP Loci in Patients of Type 2 Diabetes.

Shaheen S, Mushtaq S, Memon Z, Ghani R, Fawwad A, Jehangir F. Shaheen S, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 24. doi: 10.2174/0118715303389767251009070040. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41140208

17

Genetic Pathogenesis and Treatment of Forkhead Box A2 Hyperinsulinemia.

Ji Y, Chen C, Sang Y. Ji Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 24. doi: 10.2174/0118715303396043250929055236. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41140207

18

Exploring the Influence of Demographic and Clinical Parameters on Knowledge, Attitudes, and Practices in Type-II Diabetes Mellitus Patients in Punjab, India: A Cross-Sectional Study.

Kaur S, Mehan S, Gupta GD. Kaur S, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 22. doi: 10.2174/0118715303401307251007044510. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41133834

19

Functional Enrichment, Drug Prediction, and Molecular Docking to Identify Fibroblast-Related Biomarkers for Gastric Cancer via High-Dimensional Weighted Gene Co-Expression Network Analysis.

Lu H, Lan S, Yuan X, Li P. Lu H, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 21. doi: 10.2174/0118715303424481250929070902. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41126414

20

Incidence of Hirschsprung Disease at the Central Pediatrics Teaching Hospital in Iraq: A Pathological Overview.

Al-Zughaibi IFA, Mehdi NK, Al-Hussaniy HA. Al-Zughaibi IFA, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 20. doi: 10.2174/0118715303401696251002054047. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41121505

21

Exploration of the Mechanism of Erchen Decoction in Ameliorating Obesity by Regulating Lipid Deposition via the AMPK/SIRT1/PGC-1α Signaling Pathway.

Luo Y, Gao H, Zhao Z, Gao T, Liu Z, Yang X. Luo Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 15. doi: 10.2174/0118715303373517250919055421. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41116265

22

Buzhong Yiqi Decoction Regulates Th17 Cells Differentiation in Autoimmune Thyroiditis through PTEN/AKT-immunometabolism Axis.

Li JY, Zhao Z, Liu DL, Luo Y, Guo FY, Wang ZM, Song N, Liu ZY, Yang X. Li JY, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 15. doi: 10.2174/0118715303388096250914111152. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41116264

23

Immune-Mitochondrial Crosstalk in Pancreatic Adenocarcinoma: Systematic Identification of Prognostic Biomarkers Through Immune Dictionary Framework.

Zhao J, Zhang F, Liao X, Zhang K, Li P, Chen H. Zhao J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 15. doi: 10.2174/0118715303422686250925054821. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41116263

24

Single-Cell Profiling Identifies JUNB/SPI1-Driven Inflammatory Programs and Novel Communication Axes in Myeloid Cells of Sepsis.

Liu L, Zhao L, Tan J. Liu L, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 16. doi: 10.2174/0118715303425071250925075308. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41114487

25

Acromegaly and Morris Syndrome: Description of a Clinical Case.

De Sanctis SA, Chiloiro S, Giampietro A, Minucci A, Lauretti L, Gessi M, Rindi G, Olivi A, De Marinis L, Doglietto F, Bianchi A, Pontecorvi A, Capoluongo ED. De Sanctis SA, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 16. doi: 10.2174/0118715303424098250925063845. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41114486

26

VNN2 and IL1R2 Identified as Potential Molecular Signatures in Granulosa Cells and Blood of Patients with Polycystic Ovary Syndrome (PCOS).

Alali Z. Alali Z. Endocr Metab Immune Disord Drug Targets. 2025 Oct 16. doi: 10.2174/0118715303417042251002073727. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41114485

27

Network Pharmacology and Molecular Docking Reveal the Multi-Target Anti-Osteoporosis Mechanism of Bushen Huoxue Decoction.

Li H, Pan H, Feng M. Li H, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 10. doi: 10.2174/0118715303405254250928181948. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41088990

28

Functions of Estrogen and Estrogen-Related Receptors in Diseases of the Female Reproductive System.

Wang J, Zhu Z, Fan L, Zhang W, Li F, Liu L, Jing L, Meng K, Yuan J, Zhang H. Wang J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 10. doi: 10.2174/0118715303406667250915224123. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41088989

29

Pseudoexfoliation Glaucoma Selective Laser for Trabeculoplasty Treatment in Vietnam.

Kim TD, Ke TT, Cong AT, Minh TL, Palma GD, Santacroce L, Nguyen KC, Isacco CG. Kim TD, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 8. doi: 10.2174/0118715303387982250905154258. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41088927

30

Nonlinear Association Between Uric Acid to High-Density Lipoprotein Cholesterol Ratio and Diabetic Kidney Disease: Evidence from NHANES 2007-2018.

Wei Y, Liu C, Yu J. Wei Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 3. doi: 10.2174/0118715303369433250914053054. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41051036

31

Anti-inflammatory and Antioxidant Effects of Silibinin on Valproate-Induced Pancreatitis in Male Wistar Rats.

Khosravi MH, Asadollahi K, Ghiasi B, Adibi A, Heidarizadi S, Azizi M. Khosravi MH, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 2. doi: 10.2174/0118715303411821250914094338. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41047694

32

Mechanistic Insights into Achyranthes Bidentata Blume Water Extract in Alleviating NAFLD: PPARγ-Driven Synergistic Regulation of Lipid Metabolism and Macrophage Efferocytosis.

Li XY, Yao RM, Zou XM, Xu Y, Qiu SY, He PP, Wang LJ, Lei SS. Li XY, et al. Endocr Metab Immune Disord Drug Targets. 2025 Oct 2. doi: 10.2174/0118715303385546250912094219. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41047693

33

Improving Immune Checkpoint Therapy in the Tumor Microenvironment by Targeting T Cell Metabolism.

Wei J, An B, Dong R, Tu X, Dong Y, Liu Y, Liu Y. Wei J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 2. doi: 10.2174/0118715303400871250821103310. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41037651

34

Unraveling the Immunomodulatory Mechanisms of Quan-du-zhong Capsule in Diabetic Kidney Disease via Integrated Network Pharmacology and Experimental Validation.

Liu G, Zhou C, Xiao X, Hu S, Xie B, Wu Z, Xiao J. Liu G, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 25. doi: 10.2174/0118715303398054250823130459. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41017096

35

Associations of Mercury Exposure with Serum Sex Steroid Hormones in Children 6-18 Years from NHANES 2013-2016.

Qiu B, Lin Y. Qiu B, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 25. doi: 10.2174/0118715303396515250912001734. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41017095

36

Integrated Multiomics Analysis Identifies CDO1 as a Novel Therapeutic Target for Osteoarthritis.

Zhao Z, Wu X, Wang D, Luo W, Ma JX, Ma XL. Zhao Z, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 25. doi: 10.2174/0118715303387442250918111006. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 41017094

37

Assessment of Exercise-Stimulated Irisin in Kidney Disease: A Systematic Review.

Shintaku E, Vantini D, Ting JGB, Zuniga RDDR, Luciano da Veiga G, Alves BDCA, Encinas JF, Fonseca FLA. Shintaku E, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 19. doi: 10.2174/0118715303381483250629164853. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40990273

38

Bibliometric Analysis of Emerging Trends and Hotspots in the Links between Nonalcoholic Steatohepatitis and Diabetes Mellitus from 2004 to 2023.

Xie C, Liu T, Zhong Y, Li Z, Xu J, Zhao Z, Wang X, Gao P. Xie C, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 18. doi: 10.2174/0118715303396313250904204350. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40976898

39

Association of Anti-TPO Antibody and Inflammatory Markers with Thyroid Ultrasound Findings.

Kuloglu E, Issever K, Muhtaroglu A, Aslan S, Acar B. Kuloglu E, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 18. doi: 10.2174/0118715303429924250912052941. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40976897

40

Comparative Analysis Revealed Circulating Methylation of PDGFRB Highly Related with Rheumatoid Arthritis Related Diseases.

Shan Y, Guo M, Liu J, Wang L, Shen Y, Zhao J, Wei K, Jiang P, Shi Y, Chang C, Zheng Y, Zhao F, Li Y, Zhou M, Li C, Guo S, Liang C, Qu H, He D. Shan Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 16. doi: 10.2174/0118715303377879250831134649. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40965028

41

Analysis of Necroptosis-Related Genes and Immune Cell Infiltration in Infantile Hemangioma.

Xu Y, Chen J, Huang Z, Zhao R, Jin C, Li Z, Liu S. Xu Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 16. doi: 10.2174/0118715303388166250901114424. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40965027

42

Humanized Immune Mouse Models: Emerging Applications for Cancer Immunotherapy.

Zhong YS, Xie W, Li XJ, Ying HZ, He JQ, Yu CH. Zhong YS, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 11. doi: 10.2174/0118715303382108250825062059. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40947697

43

The Mechanism of Celosiae Semen in the Treatment of Diabetic Cataract:Based on Network Pharmacology.

Caihong S, Fang H, Song H. Caihong S, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 11. doi: 10.2174/0118715303387305250818132910. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40947696

44

Unlocking New Treatment Horizons for Celiac Disease: PRKCD Revealed as a Promising Target through Mendelian Randomization.

Zhou J, Xu Y, Wang H, Wang K, Chen C. Zhou J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 29. doi: 10.2174/0118715303410531250815124524. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40910294

45

Prognostic Value and Immune Characterization of Genes Associated with Childhood Acute Leukemia applying Single-Cell RNA Sequencing.

Lyu Z, Meng X, Xiao J. Lyu Z, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 27. doi: 10.2174/0118715303420113250818064855. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40910197

46

Fortunellin Elevates the AMPK Pathway to Reduce Lipid Deposition and Immune Disorders in Young Non-Alcoholic Fatty Liver Disease Rats.

Ping N, Qin N. Ping N, et al. Endocr Metab Immune Disord Drug Targets. 2025 Sep 1. doi: 10.2174/0118715303391165250828111133. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40908694

47

Neuroendocrine Effects of Hyperprolactinemia: Focus on Dopamine and Serotonin Systems.

Kadiri SK, Tiwari P, Khobragade DS, B S DG, Rout SK. Kadiri SK, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 26. doi: 10.2174/0118715303352625250526073105. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40873292

48

Revisiting the Association Between Beta-blockers and Psoriasis: Evidence from Real-World Data.

Zheng X, Sun J, Wang Z, Cao K, Feng C, Lv R. Zheng X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 26. doi: 10.2174/0118715303383036250807095142. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40873291

49

Jiangtang Decoction for Type 2 Diabetes and NAFLD: Integrative Analysis via Network Pharmacology, Mendelian Randomization, Molecular Docking, and In Vitro Validation.

Gong W, Lu X, Weng S. Gong W, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 22. doi: 10.2174/0118715303424915250818045151. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40873177

50

Continuous Interstitial Glucose Monitoring through a Long-Term Subcutaneous Implantable Sensor during Pregnancy in Type 1 Diabetes: A Two- Patient Case Report.

Betella N, Resi V, Gaglio A, Ciafardini A, Mazzoleni F, Vena W, Orsi E, Bossi AC. Betella N, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 18. doi: 10.2174/0118715303393466250807050121. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40851213

51

Drug-Induced Insulin Autoimmune Syndrome: A FAERS Database and Network Pharmacology Analysis.

Xiao S, Lin L, Chen XH, Lei LW, Wang M. Xiao S, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 21. doi: 10.2174/0118715303382179250808052834. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40849770

52

An Intriguing Case Report of Type 2 Autoimmune Polyendocrine Syndrome Post-SARS-CoV-2: Cause or Coincidence?

Voltan G, Graziani A, Torchio M, Mian C, Betterle C, Sabbadin C. Voltan G, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 18. doi: 10.2174/0118715303407830250807114958. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40849756

53

Neuroprotective Potential of Jimson Weed in Methotrexate-Induced Neurotoxicity: Insights into Anti-Oxidative, Anti-Inflammatory, and Anti-Apoptotic Mechanisms via Modulation of Caspase-3, Interleukin-6, and Tumor Necrosis Factor-Alpha: In Silico.

Alum EU, Krishnamoorthy R, Gatasheh MK, Famurewa AC, Subbarayan S, Vijayalakshmi P, Uti DE. Alum EU, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 15. doi: 10.2174/0118715303350736241220090850. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40849741

54

Cushing's Syndrome Presenting with Depression as the Initial Manifestation: A Case Report and Literature Review.

Xu X, Guo B, Chi X. Xu X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 13. doi: 10.2174/0118715303397972250811050815. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40814891

55

Clopidogrel-Induced Insulin Autoimmune Syndrome: Efficacy of Glucocorticoid Therapy and Continuous Glucose Monitoring.

Luo L, Xiong X, Ran J. Luo L, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 13. doi: 10.2174/0118715303394353250727192242. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40814890

56

Baicalin Induces Mesenchymal-Epithelial Transition in Chronic Pancreatitis Through Upregulation of E-Cadherin.

Dou B, Ma K, Wang F, Li S, Sun M, Zhu Y, Wang F. Dou B, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 13. doi: 10.2174/0118715303373325250723143559. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40814889

57

Association of Glucose-Dependent Insulinotropic Polypeptide Receptor Polymorphisms rs3848460 and rs3895874 with the Risk of Gestational Diabetes Mellitus.

Ray GW, Zhang H, Shao T, Yang T, Wei Y, Li M, Che X, Zeng Q, Guo R. Ray GW, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 5. doi: 10.2174/0118715303367483250728105845. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40770477

58

Assessment of Sonographic Ovarian Volume as a Potential Predictor of Polycystic Ovarian Syndrome (PCOS): A Hospital-Based Cross-Sectional Study.

Ali B, Hadadi I, Adam M, Faqihi WA, Sayed M, Alotaibi SA, Gareeballah A, England A. Ali B, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 4. doi: 10.2174/0118715303396709250721152449. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40765087

59

Magnesium Level and Related Factors in Type 2 Diabetes Mellitus: A Cross-Sectional Study.

Konur K, Polat HB, Karavar E, Ayaz T. Konur K, et al. Endocr Metab Immune Disord Drug Targets. 2025 Aug 1. doi: 10.2174/0118715303411661250721141050. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40760759

60

Severe Hypercalcemia Following Pembrolizumab Therapy: A Case Report and A Literature Review.

Lazzaroni M, Angelini F, Guglielmi R, Novizio R, Iadevaia A, Andreadi A, Papini E. Lazzaroni M, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 31. doi: 10.2174/0118715303409910250725043347. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40755097

61

Diagnostic Biomarkers and Targeted Drug Prediction for Acute Kidney Injury: A Computational Approach.

Zhou L, Pan L, Gao J, Jiang Y, Li T, Li R. Zhou L, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 30. doi: 10.2174/0118715303417142250724042300. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40754871

62

Genetic Prediction of Causal Association Between Celiac Disease and Thyroid Function: A Two-Sample Mendelian Randomized Study.

He X, Lv H, Yu W, He J, Xie Y, Zhou L, Wu H, Guo L, Yang X. He X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 28. doi: 10.2174/0118715303364014250713045734. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40735990

63

Danshenol A Mediates the Proliferation and Differentiation of Adipocytes in Thyroid-Associated Ophthalmopathy.

Chen Y, Min J, Yu X, Ni H, Jin Y. Chen Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 24. doi: 10.2174/0118715303382831250712200617. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40734440

64

The Mediating Role of Blood Metabolites in the Association between Basal Metabolic Rate and Obstetrical Disorders: A Mendelian Randomization Analysis.

Gan Y, Tan X, Tang Y, Shi Q, Qi H. Gan Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 24. doi: 10.2174/0118715303400445250718112316. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40734439

65

Metabolic Disease Management through Natural Products: A Thorough Exploration.

Prabhakar PK. Prabhakar PK. Endocr Metab Immune Disord Drug Targets. 2025;25(12):915-917. doi: 10.2174/0118715303426691250717134755. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40708511 No abstract available.

66

NLRP3 Inflammasome: A New Perspective on Revealing Hotspots and Trends in Uric Acid Metabolism Disorders through Bibliometric Analysis.

Xu Y, Wang Y, Lu C, Liu Z, Lin Z, Zhang X, Zhang B. Xu Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 22. doi: 10.2174/0118715303376897250702230058. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40698684

67

The Combination Therapy of Pasireotide LAR Plus Pegvisomant and Cabergoline Relieved Acromegaly-Related Headache in a Female Patient with AIP-Mutated Acromegaly: A Case Report.

Giambò P, Chiloiro S, Giampietro A, Mattogno PP, Lauretti L, De Marinis L, Bianchi A, Doglietto F, Pontecorvi A. Giambò P, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 18. doi: 10.2174/0118715303400381250715180534. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40692146

68

Associations of Anthropometric Indicators with Bone Mineral Density and the Risk of Bone Fractures and Falls: A Large-Scale Genetic Correlation Study.

Hu X, Gao ZX, Zhu YY, Li S, Ding WW, Pan HF, Wang P. Hu X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 18. doi: 10.2174/0118715303369995250702111723. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40692145

69

Identifying AIM2 Circulating Methylation Levels as a Novel Diagnostic Biomarker for Rheumatoid Arthritis Using Targeted DNA Methylation Sequencing.

Zhao J, He B, Shan Y, Wei K, Jiang P, Shi Y, Chang C, Zheng Y, Zhao F, Li Y, Zheng Y, Jin Y, Lv X, Guo M. Zhao J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 17. doi: 10.2174/0118715303401357250707080740. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40685733

70

Palmatine Ameliorates High-Temperature and High-Humidity-Induced Enteritis Via Mitophagy and NLRP3 Inflammasome Degradation.

Mo X, Mi T, Liu W, Wang Y, Wu Y, Huang X, Chen S, Luo H. Mo X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 15. doi: 10.2174/0118715303348448250605071743. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40671221

71

Yipishen Xiezhuo Jiedu Decoction in Ameliorating Kidney Damage Through miR-223/NLRP3/ Caspase-1 Pathway.

Weng J, Zheng D, Chen H, Huang Z, Wu X, Zheng W, Yu Z, Xu Q. Weng J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 10. doi: 10.2174/0118715303402744250704071034. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40653837

72

Omalizumab as an Effective Therapy for Testosterone-induced Angioedema in a Transgender Person: A Case Report.

Marinelli L, Motta G, Castella L, Voltolini S, Romano A, Giudice AD. Marinelli L, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 10. doi: 10.2174/0118715303399441250701073138. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40653836

73

Ectopic ACTH Syndrome Caused by Pheochromocytoma: A Case Report and Systematic Review.

Huang J, Lin C, Fang L, Gu L, Cai X, Zeng H, Chen K, Mu Y, Liu J. Huang J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 9. doi: 10.2174/0118715303372676250628161600. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40641027

74

Chinese Patent Medicine Nei-Xiao-Pian Shrinks Thyroid Nodules by Regulating Proliferation and Apoptosis of Cells via Inhibiting the IL-6/JAK2/STAT3 Signaling Pathway.

Zhao YT, Yang Y, Mei WT, Chen T, Wei W, Wu YC, Yu X, Huang F. Zhao YT, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 9. doi: 10.2174/0118715303380988250627113427. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40641026

75

The Evolution of Pediatric MAFLD Research (2014-2023): A Decade-Long Bibliometric Analysis of Emerging Trends.

Li T, Zhang X, Wang D, Zhang L, Wu Q, Yan W, Cui F, Huang M, Hua P, Cui X. Li T, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 7. doi: 10.2174/0118715303404437250611123553. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40626543

76

Iodine and Hypothyroidism.

Fan X, Guo S, Wu S, Fan Y, Zhang Q. Fan X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 4. doi: 10.2174/0118715303355789250321080037. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40621769

77

Review of Traditional Chinese Medicine in the Treatment of Non-Alcoholic Fatty Liver Disease.

Lu Y, Xie Y, Yang X, Nie L, Cheng Z, He Y, Lv T, Wu Q, Zhou X. Lu Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jul 2. doi: 10.2174/0118715303361217250629091316. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40611425

78

Relationship between Aging and Ketogenic Diet: A Bibliometric Analysis (1995-2025).

Elgun T, Isik AA, Ciraci E, Gundogan GI, Ziksahna K, Arslan HI. Elgun T, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jun 30. doi: 10.2174/0118715303376457250617154223. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40598723

79

Targeted Therapeutic Approach Employing In Silico Methods to Identify Potent Flavonoids in Cervical Cancer.

Sharma S, Mishra A, Pandey P. Sharma S, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jun 30. doi: 10.2174/0118715303362788250616052258. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40598722

80

The Anti-Osteoporosis Effects of Panax japonicus via Downregulation of Inflammatory Factors: A Network Pharmacology and Ovariectomized Rat Model Study.

Zhang Y, Liu Y, Zhang Y, Shi X, Li Y, Pan Y. Zhang Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jun 20. doi: 10.2174/0118715303371787250609162705. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40574401

81

Denticleless E3 Ubiquitin Protein Ligase Homolog as a Potential Biomarker for Adrenocortical Carcinoma Screening.

Yan X, Pang LX, Lu X, Chen S, Li L, Liang XH, Lu DC, Luo ZJ. Yan X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jun 20. doi: 10.2174/0118715303334496250518033852. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40574400

82

The Inflammatory Response in Metabolic Syndrome.

Martínez-Pérez LA, González-Sánchez GD, Martínez-Esquivias F, Becerra-Ruiz JS, Guzmán-Flores JM. Martínez-Pérez LA, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jun 19. doi: 10.2174/0118715303385742250610120711. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40551699

83

Recent Progression and Treatment Approaches of Kidney Fibrosis: Evidence to Clinic Approach.

Sharma M, Khanna M, Kumar P, Gupta GD, Sharma K. Sharma M, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jun 19. doi: 10.2174/0118715303374764250612052832. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40551698

84

Genome-wide Association Studies of the Pathogenic Sphingosine-1-Phosphate Gene in Ulcerative Colitis.

Chen H, Shang J, Zhao S, Xu L, Shen H. Chen H, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 29. doi: 10.2174/0118715303354936250523030225. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40454507

85

Integrative Network Pharmacology Prediction of the Mechanisms of Tri-Ka-Tuk: A Traditional Thai Herbal Formula.

Singthong P, Songserm N, Balasubramani SP, Krongkeha W, Dechakhamphu A. Singthong P, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 27. doi: 10.2174/0118715303374703250429111617. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40444620

86

Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis Studies.

Hashempour Z, Esmaeili F, Tabatabaei-Malazy O, Mosallanejad A, Panahi G. Hashempour Z, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 26. doi: 10.2174/0118715303375795250521041740. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40442919

87

Management of Steroid-Induced Diabetes: A Review of Herbal Medications and Their Role in Modulating Insulin Signaling Pathways.

Gupta J, Verma N, Wal A, Panda KC, Yeleti VV, Singh B, Mahajan S, Kandhari H, Wal P. Gupta J, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 23. doi: 10.2174/0118715303327497241214054628. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40417756

88

Effects of TGMXD-208, a Novel PI3K Inhibitor, on Adjuvant-induced Arthritic Rats by Suppressing PI3K/AKT Signaling Pathway.

Yin J, Wang J, Su W, Tang R, Qin Z, Jia X, Ma X, Gui S. Yin J, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 22. doi: 10.2174/0118715303373717250509063328. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40415316

89

Sterile Inflammation and Cell Death Pathways in Liver Ischemia-Reperfusion Injury: A Review and Perspective.

Huang W, Meng W, Zhao J, Zhang B. Huang W, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 19. doi: 10.2174/0118715303401342250514102731. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40396312

90

Immunocytes Play a Crucial Role as Mediators in the Protective Effects of D-β-Hydroxybutyrate Dehydrogenase 1 against Type 2 Diabetes Mellitus: A Mendelian Randomization Study.

Liu YY, Zhang YY, Wan Q. Liu YY, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 19. doi: 10.2174/0118715303380282250225071730. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40396311

91

Determination of Nitrogen Metabolism-Related Prognostic Signatures for Forecasting Bladder Cancer Prognosis.

Cheng H, Li Y, Shen S. Cheng H, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 16. doi: 10.2174/0118715303371907250514054016. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40390219

92

Study on Immune Characteristics and Gene Polymorphisms of Hypertension Patients.

Wei X, Wang Z, Tang Y, Tian L, Xu Y, Zheng M. Wei X, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 16. doi: 10.2174/0118715303365110250209092351. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40390218

93

Association between Serum Osteocalcin and Cardiometabolic Risk Factors in Latent Autoimmune Diabetes in Adults: Insights from Glutamic Acid Decarboxylase Subgroup Analysis.

Fu X, Xu Z, Xu J, Tan Q, Wang Z. Fu X, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 13. doi: 10.2174/0118715303364381250428100830. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40370240

94

EphrinB2 Ameliorates Renal Fibrosis by Inhibiting the TGF-β/Smad3 Signaling Pathway and the Inflammation Response.

Yuan C, Zhou Q, Chen F, Gao X, Yusufu A, Wu X, Ni L. Yuan C, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 12. doi: 10.2174/0118715303366454250507042518. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40357778

95

Evaluation of Stigma Toward Fatty Liver Disease.

Fouad Y, Mostafa AM, Pan Z, Nafady S, Rasmy HS, Shaltout SW, Hassan D, Alboraie M, Eslam M. Fouad Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 6. doi: 10.2174/0118715303359141250420070406. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40337974

96

Knowledge Gaps in Patients Undergoing Thyroid Fine-Needle Aspiration Biopsy.

Şenoymak MC, Babacanlar N, Erbatur NH, Deniz F, Yönem A. Şenoymak MC, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 6. doi: 10.2174/0118715303364657250415115259. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40337973

97

Single-cell RNA Sequencing Analysis Reveals the Regulatory Functions of Copines Family Genes in Testicular Cancer Progression.

Li N, Yu K, Huang D, Zhu X, Lin Z. Li N, et al. Endocr Metab Immune Disord Drug Targets. 2025 May 6. doi: 10.2174/0118715303375462250430055914. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40337972

98

Steroid Use, Adrenal Suppression, and Emergency Department Visits in COPD Patients: A Cross-Sectional Study.

Karahan T, Dişel NR, Taşkın Ö, Dağlıoğlu G, Tuğcan MO, Sebe A, Akpınar AA. Karahan T, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 29. doi: 10.2174/0118715303397988250428050120. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40325544

99

Current Status and Future Prospects of Immune Checkpoint Inhibitors Research in the Treatment of Multiple Myeloma.

Guo X, Liu Y, Zhang L, Hao Z, Chu S, Zhou W, Li L. Guo X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 29. doi: 10.2174/0118715303379372250417112236. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40304327

100

Male Osteoporosis: A Comprehensive Review of Treatment Approaches in Modern Pharmacotherapy and Traditional Chinese Medicine Interventions.

Wang Y, Chen G, Zhou Z, Zhao W, Wong SK, Wang Y, Chin KY. Wang Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 29. doi: 10.2174/0118715303206506250404180458. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40304326

101

Unraveling the Lipidomic Determinants of Atrial Fibrillation: An Extensive Mendelian Randomization Study.

Ye L, Lin D, Chen F, Huang X, Wu X. Ye L, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 29. doi: 10.2174/0118715303378914250418095928. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40304325

102

Evaluation of the Space GlucoseControl System for Managing Stress-Induced Hyperglycemia in ICU Patients: Efficacy and Safety Assessment.

Liu PC, Fan DD, Bao QY, Jiang XM, Lu J. Liu PC, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 29. doi: 10.2174/0118715303346311250415111740. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40304324

103

CD27 and GZMK as Co-Biomarkers in Rheumatoid Arthritis and Crohn's disease and Mediate Immune Imbalance.

Zheng L, Zeng Y, Fang M, Heng H, Luo Y, Zhong J. Zheng L, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 29. doi: 10.2174/0118715303372365250421114853. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40304323

104

Esketamine Reduces Lung Injury Caused by Limb Ischemia-Reperfusion by Regulating Oxidative Stress via the TLR4/NF-κB/NLRP3 Pathway.

Wang M, Ma Q, Wang W, Cun J, Wen H. Wang M, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 29. doi: 10.2174/0118715303393744250423100211. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40304322

105

Modulation of the Inflammatory Signature in an Experimental Autoimmune Encephalomyelitis Model through Treatment with Fasciola hepatica-Derived Recombinant Fatty Acid Binding Protein (rFh15).

Hajizadeh M, Falak R, Sahlolbei M, Robat-Jazi B, Sadeghipour A, Bolouri MR, Rashidi N, Masoori L, Kazemi MH, Samei A, Dalouchi F, Jalallou N, Oraei M, Meamar AR, Saboor-Yaraghi AA. Hajizadeh M, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 22. doi: 10.2174/0118715303336969250328052842. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40265426

106

Comprehensive View of Magnesium Physiology.

Jawaid S, Shams S, Kharb D, Al-Bar OA, Zeyadi M, Al Hazmi IS, Kumar V, Anwar F. Jawaid S, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 21. doi: 10.2174/0118715303364703250224053714. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40264314

107

Comprehensive Transcriptomic and Bioinformatic Analysis of the Mechanism of Buzhong Yiqi Decoction in the Improvement of Diabetic Nephropathy.

Zhang X, Wei W, Liu Z, Gao H, Guo F, Liu D, Yin Y, Yang X. Zhang X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 21;25(13):1099-109. doi: 10.2174/0118715303379062250327184950. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40264313 Free PMC article.

108

The Liraglutide-Induced Pemphigus Vulgaris: A First Case Report Highlighting Autoimmune Risks of GLP-1 Receptor Agonists.

Cai S, Zhang Z, Ding W, Zhou S, Qiu X, Hou F, Wu C, Shen Z, Feng X, Jiang L. Cai S, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 21. doi: 10.2174/0118715303361089250320050246. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40264312

109

Evaluation of Betatrophin, Chemerin, and Kisspeptin Levels in Acromegaly Patients.

Cayan DA, Topsakal S, Avci E. Cayan DA, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 21. doi: 10.2174/0118715303375180250312035323. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40264311

110

A Systematic Review of Research Hotspots and Global Trends in Primary Ovarian Insufficiency Research.

Zhang Y, Lei S, Li M, Lei X, Liu X, Nong W, Zhang J. Zhang Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 21. doi: 10.2174/0118715303339221250319041923. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40264310

111

Diabetic Ketoacidosis: Considerations and Residual Controversies in Management After the 2024 ADA, EASD, JBDS, AACE, and DST Joint Consensus.

Ciafardini A, Vena W, Betella N, Pigni S, Mirani M, Altieri VM, Mazziotti G, Lania AG, Bossi AC. Ciafardini A, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 18. doi: 10.2174/0118715303374972250407065308. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40257014

112

Exploring the Genetic Link between Irritable Bowel Syndrome and Polycystic Ovary Syndrome: Bidirectional Mendelian Randomization and Machine Learning Approaches.

Gao Z, Mei Z, Zhang Y, Lv S, Song J, Ye W. Gao Z, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 16. doi: 10.2174/0118715303363459250317084005. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40247811

113

Identification of Hub Neutrophil Coexpressed Genes in Acute Pancreatitis via Machine Learning.

Guan Y, Xu Z, Liang L, Deng W, Qin Z, Yang J, Qin S. Guan Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 16. doi: 10.2174/0118715303375487250225114210. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40247810

114

Human-like Skin Tissue Graft Generated Using Human UmbilicalCordBlood Mesenchymal Stem Cells and Acellular Amniotic Membrane: A New Approach in Reconstructive Medicine.

Nguyen BT, Huynh TD, Nguyen HK, Hoang HK, Tran TTT, Nhan HN, Nguyen HTT, Ngo QMT, Nguyen KT, Inchingolo F, Santacroce L, Nguyen KC, Isacco CG. Nguyen BT, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 11. doi: 10.2174/0118715303370737250324063647. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40231530

115

Integrating Gut-Brain Axis: Exploring the Neurogastrointestinal Interactions and Therapeutic Potentials in Autism Spectrum Disorder.

Kumar M, Mehan S, Sharma T, Kumar A, Khan Z, Sharma AK, Kumar N, Gupta GD. Kumar M, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 7. doi: 10.2174/0118715303369166250325110016. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40207766

116

Exploring the Effects of Propolis on Oral Mucositis in Patients Undergoing Chemotherapy: A Systematic Review and Meta-Analysis.

Chang YC, Porreca A, Massafra R, Lin GM, Vitale E. Chang YC, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 7. doi: 10.2174/0118715303356011250307070928. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40197195

117

Global Scientific Trends in the Use Of Mesenchymal Stem Cells for the Treatment of Diabetes Mellitus from 2000 to 2023: A Bibliometric Study.

Sun Z, Wang Y, Chen K, Zheng W, Wang Y, Zhu M, Yang M, Zhou X. Sun Z, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 7. doi: 10.2174/0118715303348724250310082224. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40197194

118

Global Trends in Research of Intestinal Cells and Type 2 Diabetes Mellitus: A Bibliometric and Visualized Analysis from 2004 to 2023.

Li Z, Zhang S, Cao R, Wu B, Han K, Yang W, Chen S, Zhang X, Han X, Guo L. Li Z, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 4. doi: 10.2174/0118715303353611250312043509. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40192044

119

A Rare Case of Ischial Tubercle Pressure Sore with Secondary Periperineal Necrotizing Fasciitis.

Wang P, Liu Y, Wang J, Guo Q, Wang X. Wang P, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 4. doi: 10.2174/0118715303385272250320042418. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40192043

120

Type 2 Diabetes Mellitus in Saudi Arabia: Prevalence, Risk Factors, and Management Strategies: A Review.

Aldahash R, Aldossari K, Aljohanni N, Alsabaan F, Alzahrani W, Alwabel A, Alhendi AMN. Aldahash R, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 3. doi: 10.2174/0118715303361062250122100238. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40183267

121

Shared Genetic Basis, Biological Function and Causal Relationship Between Sleep Traits and Hypothyroidism: Evidence from a Comprehensive Genetic Analysis.

Shi Y, Guo M, Wang Y, Zeng G, Li W, Wu M, Li B. Shi Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 3. doi: 10.2174/0118715303348704250227014802. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40183266

122

Metabolomics: An Emerging Approach to Understand the Pathogenesis of Reactive Arthritis.

Dubey D, Kumari R, Singh A, Shaw P, Kothari A, Ranjan S, Mamgain G, Yadav S, Kumar S. Dubey D, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 3. doi: 10.2174/0118715303309669250319083147. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40183265

123

A Comparison between LTT and CFSE Proliferation Tests in Patients with Inborn Errors of Adaptive Immunity.

Shad TM, Taghizadeh N, Delavari S, Aghamohamadi N, Mehrabadi AZ, Salami F, Mohammadi S, Salehi H, Fekrvand S, Tavakol M, Fathi N, Chavoshzadeh Z, Mesdaghi M, Ghadrdan M, Shafiei A, Rezaei N, Yazdani R, Abolhassani H. Shad TM, et al. Endocr Metab Immune Disord Drug Targets. 2025 Apr 3. doi: 10.2174/0118715303363026250312063731. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40183264

124

Construction of a Single-cell Atlas of Thyroid Cancer.

Song K, Wang Y, Wang Y, Liu J, Yao W, Chu Y, Qu Y, Song X, Zhou J. Song K, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 10. doi: 10.2174/0118715303359688250209090544. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40183263

125

Exploring and Validating Prognostic Biomarkers Related to Sphingolipid Metabolism in Gastric Cancer through Machine Learning.

Chai J, Guo C, Wang H, Wei J, Yu Y, Li X, Zhang H, Guo X. Chai J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 26. doi: 10.2174/0118715303362774250219065927. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40148306

126

Falsely Elevated Estradiol Levels Due to Heterophile Antibody Interference: A Case Report and Literature Review.

Guo Y, Wei B, Dai W, Zhang G. Guo Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 20. doi: 10.2174/0118715303352682250219044719. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40114576

127

Repurposing of Chinese Medicine Extract against Staphylococcus Aureus: Assessing the Antibacterial and Anti-Transfer Activity of Plasmid in Drug-Resistant Bacteria.

Tong Y, Kang J, Wang Q. Tong Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 20. doi: 10.2174/0118715303352305250214071027. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40114575

128

Akkermansia muciniphila Delays the Progression of Diabetic Nephropathy by Reducing the Accumulation of Uremic Toxins in the Feces and Peripheral Blood.

Song X, Yao M, Zhang J, Huang B, Li X, Zhang M, Cui J. Song X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 20. doi: 10.2174/0118715303343599250210103212. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40114574

129

Differences in Thyroid Autoimmunity and Thyroid Function Tests Between Individuals with and without Obesity: Is There a Correlation with Obesity Degree?

Altuntaş SÇ. Altuntaş SÇ. Endocr Metab Immune Disord Drug Targets. 2025 Mar 20. doi: 10.2174/0118715303342780250219111457. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40114573

130

Navigating Cardiovascular Challenges of Obesity: Exploring Preventive Approaches.

Sinha V, Roy S, Shinde S, Mondal D, Dixit V, Dwivedi D, Pandey SK, Gupta RK, Vishwakarma NK, Shukla D. Sinha V, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(12):918-940. doi: 10.2174/0118715303317750250210055338. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40108925 Free PMC article. Review.

131

Ultra-Processed Food Consumption during the COVID-19 Pandemic.

Triggiani D, Triggiani V, Lisco G. Triggiani D, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 17. doi: 10.2174/0118715303373150250310061411. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40103475 No abstract available.

132

Obesity and Childhood Leukemia in Brazil: Biological, Regional, and Environmental Insights.

Degasperi GR, Fonseca MC, Carvalho VDS. Degasperi GR, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 10. doi: 10.2174/0118715303359757250213064623. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40070066

133

Development of a Novel 11-Gene Signature Related to Immune Subtypes for Fibromyalgia.

Zhao W, Wang P. Zhao W, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 10. doi: 10.2174/0118715303365068250303042017. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40070065

134

Epstein-Barr Virus and Human Papillomavirus Infection in Papillary Thyroid Carcinoma: A Correlation Study.

Zhao R, Lu Y, Teng W, Xue X, Zhang Y, Huang S, Chen X. Zhao R, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 10. doi: 10.2174/0118715303355722250127061453. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40070064

135

The Dynamic Changes in Maternal Thyroid Parameters Across the Three Trimesters and Their Differential Effects on the Occurrence of Adverse Obstetric Outcomes.

Yang Z, Sun J, Wang J, Jin X, Gao Y, Lin Z, Fan C, Luo D, Wang D, Teng W, Shan Z, Li J. Yang Z, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 4. doi: 10.2174/0118715303351648250120113846. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40045850

136

The Differential Diagnosis between Pseudo Cushing's Syndrome and True Cushing's Syndrome in a Septic Patient in the Pre-Agonal Phase: A Case Report.

Sanctis SA, Chiloiro S, Tanzarella ES, Bongiovanni F, Giampietro A, Infante A, Pascale G, Marinis L, Antonelli M, Pontecorvi A, Bianchi A. Sanctis SA, et al. Endocr Metab Immune Disord Drug Targets. 2025 Mar 4. doi: 10.2174/0118715303346706250206070813. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40045849

137

Integrated Bioinformatics Analysis Revealing that the NSDHL Gene Might Be Associated with the Progression of Western HFD/SW-Induced Hepatocellular Carcinoma.

Hong J, Pan B, Yan Z, Zhai XF, Liu Y. Hong J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 28. doi: 10.2174/0118715303356256250129063049. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 40033501

138

The Effect of Chrysin Nanocrystal on the Thyroid Gland of Rats Exposed to Chlorpyrifos.

Farkhondeh T, Ahrari F, Rajabi S, Alemzadeh E, Mesbahzadeh B, Rezaei M, Ziafati Majidi S, Samarghandian S. Farkhondeh T, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 19. doi: 10.2174/0118715303329277250120104421. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39976093

139

A Comparative Analysis of COVID-19-Associated and Non-COVID-19-Associated Mucormycosis.

Kömür S, Candevira A, İnala AS, Kuşcua F, Kurtarana B, Memişoğlub F, Karaoğlanc İ, Taşovaa Y. Kömür S, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 19. doi: 10.2174/0118715303335275250116055824. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39976092

140

1-Deoxynojirimycin Ameliorates Diabetic Liver Injury by Regulating AMPK/SIRT1 and Oxidative Stress in db/db Mice.

Li Y, Cao Y, Tian YY, Chen WW, Wang J, Zhang MM, Wang SW, Xie YH. Li Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 19. doi: 10.2174/0118715303327499250104221937. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39976091

141

Empagliflozin and Arterial Stiffness in Patients with Type 2 Diabetes: A Real-World Case-Control Study.

Tassone F, Ferreri C, Rossi A, Borretta G, Pastorini G, Anastasio F, Feola M. Tassone F, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 18. doi: 10.2174/0118715303372020250131060159. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39976018

142

Screening Co-Diagnostic Genes for Lung Adenocarcinoma and Myocardial Infarction and Analysis of the Molecular Functions and Drug Value of the Genes.

Du N, Liang M, Liu Z. Du N, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 11. doi: 10.2174/0118715303374928250130113050. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39950480

143

Integrative Analysis of Metabolomic and Transcriptomic Data Reveals Metabolic Signatures and Major Metabolic Pathways in Primary Aldosteronism.

Lai X, Yang T, Wei C, Zhu S, Li J. Lai X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 11. doi: 10.2174/0118715303361250250119035029. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39950479

144

Transporter Associated with Antigen Processing Proteins (TAP-1 and TAP-2) Gene Expression of MHC-I Downregulated in Oral Squamous Carcinoma.

Singh V, Dwivedi S, Agrawal R, Ps MR, Bansal A, Agarwal A, Misra S. Singh V, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 11. doi: 10.2174/0118715303344715241225184322. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39950478

145

Advances in Sources, Content Determination, and Bioactivity of 20α-Hydroxyprogesterone.

Li L, Yan S, Cheng Y, Zhong C, Chen C, Gao X. Li L, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 10. doi: 10.2174/0118715303302957250117052100. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39950296

146

ICPi-Induced Graves' Disease with Pre-existing Autoimmune Thyroid Disorders: A Case Report and Literature Review.

Wang X, Chen D, Shi Y, Yang T, Zheng X. Wang X, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 10. doi: 10.2174/0118715303317264250116095028. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39950295

147

Sars-Cov-2 Infection as Catecholamin Crisis in Pheocreomocitoma: A Case Report.

Novizio R, Corsello A, Rizzo GE, Pontecorvi A, Locantore P. Novizio R, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 10. doi: 10.2174/0118715303348376250103113426. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39950294

148

Abnormal Elevation of the Expression of Costimulatory Molecule CD226 in Graves' Disease: Two Cross-Sectional Studies.

Huang Z, Liu X, Cai T, Jiang Y, Wu Y, Zhang X, Song RH, Zhang JA. Huang Z, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 12. doi: 10.2174/0118715303337480250107052116. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39945256

149

Prediction of the Prognosis and Treatment Responses Based on the Characteristics of Disulfidptosis-Related Genes in Patients with Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.

Kang M, Jiang S, Chen H, Xu Y, Mo H. Kang M, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 12. doi: 10.2174/0118715303374396250129111340. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39945255

150

Relative Fat Mass Associated with Hyperuricemia in Adults: A Cross-Sectional Study.

Gu T, Wang Z, Yang Q, Xu M, Shao X, Xue B. Gu T, et al. Endocr Metab Immune Disord Drug Targets. 2025 Feb 6. doi: 10.2174/0118715303344427241218114648. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39936429

151

The Role of the Toll-Like Receptor Signaling Pathway in Autoimmune Diseases and Treatment with Traditional Chinese Medicine: A Literature Review.

Wang Y, Bao L, Liu M, Tang X, Liu H, Liang X, Liu Y. Wang Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 21. doi: 10.2174/0118715303340093241227094242. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39844540

152

Treatment of Primary Hypothyroidism by Slow-Release Liothyronine Monotherapy.

Azizi F, Amouzegar A, Abdi H, Masoumi S, Mehran L. Azizi F, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 21. doi: 10.2174/0118715303321830241227112420. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39844539 Clinical Trial.

153

Potassium-Rich, Gluten-Free Diets for Patients with Sjögren's Syndrome: A Hypothesis.

Rastmanesh R, Isacco CG, Vellingiri B, Pepoyan A, Marotta F, Tekin I, Catanzaro R. Rastmanesh R, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 17. doi: 10.2174/0118715303341983241223041524. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39835572

154

Protective Effects of Monoacylglycerol Lipase Inhibition in Rats with Severe Acute Pancreatitis and Its Possible Mechanism.

Su T, Xu H, Wang R, Xiao T, Wang J, Zhao S. Su T, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 17. doi: 10.2174/0118715303335207241225091132. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39835571

155

Effect of a Medication Adherence Education Intervention on Clinical Outcomes in Adults with Type 2 Diabetes Mellitus: A Randomized Controlled Trial Study.

Esfanjani AT, Zare M, Mardi A, Haghighian-Roudsari A, Rafraf M, Iranparvar-Alamdari M, Hackett D, Shaghaghi A, Jafarabadi MA. Esfanjani AT, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 17. doi: 10.2174/0118715303335172241216102015. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39835570 Clinical Trial.

156

Metabolomic Analysis of the Effects of Canagliflozin on HFpEF Rats and Its Underlying Mechanism.

Zhang G, Zuo Q, Ma S, He L, Wang Z, Zhai J, Zhang T, Wang Y, Guo Y. Zhang G, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 17. doi: 10.2174/0118715303373321250108174111. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39835569

157

Dietary and Nutritional Aspects of Metabolic Syndrome Management: An Overview.

Singh P, Kaushik U, Mir SR, Kukreti N, Visht S. Singh P, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(12):941-952. doi: 10.2174/0118715303316445241108100017. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39817379 Free PMC article. Review.

158

Global Publication Trends and Research Hotspots of Diabetes and Osteoporosis.

Zhang Y, Ren Q, Zhao P, Zou Q. Zhang Y, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(12):1017-1030. doi: 10.2174/0118715303325060241211094931. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39817378 Free PMC article. Review.

159

Relationship between Pituitary Gland and Stem Cell in the Aspect of Hormone Production and Disease Prevention: A Narrative Review.

Sharma A, Kumar R, Saini A, Dagar W, Kapoor K, Goel K, Chawla I, Dhanawat M. Sharma A, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(7):509-526. doi: 10.2174/0118715303314551241031093717. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39812047 Free PMC article. Review.

160

Protective Effect of Vitamin D Supplementation Against Atherosclerotic Cardiovascular Disease in Type 1 Diabetes Mellitus Model.

Alhazmi AS. Alhazmi AS. Endocr Metab Immune Disord Drug Targets. 2025 Jan 13;25(15):1262-72. doi: 10.2174/0118715303341809241022110317. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39812046 Free PMC article.

161

Oral Microbiota Associated with Clinical Efficacy of Ustekinumab in Crohn's Disease.

Xu F, Xie R, He L, Wang H, Zhu Y, Yang X, Yu H. Xu F, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 13;25(15):1228-39. doi: 10.2174/0118715303363951241209060903. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39812045 Free PMC article.

162

Bioinformatics Analysis Reveals Microrchidia Family Genes as the Prognostic and Therapeutic Markers for Colorectal Cancer.

Liu B, Chen L, Chen H, Pan J, Yu C. Liu B, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 13;25(15):1240-61. doi: 10.2174/0118715303367767241231113110. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39812044 Free PMC article.

163

The Potential of Natural Products in Metabolic Disease Management: A Thorough Exploration of the Case of Uganda.

Ahikiriza AA, Bukke SPN, Yadesa TM, Nicholas B, Daniel K, Moses K, Bonny SM, Prabhakar PK. Ahikiriza AA, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(12):953-959. doi: 10.2174/0118715303320109241014064209. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39810524 Free PMC article. Review.

164

The Polygenic Nature of Multiple Sclerosis: Genetic Variants, Immunological Modulation, and Environmental Connections.

Khan Z, Mehan S, Maurya PK, Kumar A, Gupta GD, Narula AS, Kalfin R. Khan Z, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(7):527-559. doi: 10.2174/0118715303325979241206115417. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39810445 Free PMC article. Review.

165

Plasma Hepatic Transaminases and Incidence of Metabolic Syndrome Before Midlife in Military Adults: A CHIEF Cohort Study.

Liu FC, Chen KW, Tsai KZ, Chu CC, Lin YC, Chang YC, Lin GM. Liu FC, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(7):582-592. doi: 10.2174/0118715303326392241022050205. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39806968 Free PMC article.

166

Lingguizhugan Decoction in the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Lu Y, Nie L, Yang X, Zhao Z, Wang Y, Wu Q, Zhou X. Lu Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 9;25(13):1060-72. doi: 10.2174/0118715303323071241022053842. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39806967 Free PMC article.

167

Network Pharmacology Unveils Multi-Systemic Intervention of Panax notoginseng in Osteoporosis via Key Genes and Signaling Pathways.

Wang Q, Wang X, Wu K, Wu W, Wei Z, Feng W. Wang Q, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 9;25(15):1211-27. doi: 10.2174/0118715303335018241107084224. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39806966 Free PMC article.

168

Contribution of Type 2 Diabetes Susceptible Gene GCKR Polymorphisms Rs780094 and Rs1260326 to Gestational Diabetes Mellitus: A Meta-Analysis.

Zhang Y, Wang K, Ji C, Lin Y, Liu Z, Chen J, Zheng F, Yang X, Sun Y. Zhang Y, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 9. doi: 10.2174/0118715303313654241101042033. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39806965

169

Associations of Chronic Hepatitis B and Nonalcoholic Fatty Liver Diseases with New-Onset Metabolic Syndrome in Military Personnel before Midlife: A Cohort Study.

Tsai KZ, Liu PY, Lin YC, Huang CM, Wang HS, Lin GM. Tsai KZ, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 9;25(13):1073-81. doi: 10.2174/0118715303323078241022050619. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39806964 Free PMC article.

170

Cardiovascular Findings and Effects of Caffeine on Experimental Hypothyroidism.

Yuksel D, Ozmen O. Yuksel D, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(10):777-788. doi: 10.2174/0118715303315657240819114052. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39806963

171

A Case Report of Recurrent Primary Pituitary Abscess: Challenges in Diagnosis and Treatment.

Ozaydin D, Demir AN, Kartum TA, Vergili E, Kadioglu P, Tanriover N. Ozaydin D, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 8;25(14):1205-10. doi: 10.2174/0118715303338996241021094336. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791181 Free PMC article.

172

Gut Microbiota and Diabetes: Pioneering New Treatment Frontiers.

Shakya R, Sivakumar PM, Prabhakar PK. Shakya R, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(10):767-776. doi: 10.2174/0118715303342579241119155225. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791180 Free PMC article. Review.

173

Do SGLT2 Inhibitors Protect the Kidneys? An Alternative Explanation.

Ilany J. Ilany J. Endocr Metab Immune Disord Drug Targets. 2025 Jan 8. doi: 10.2174/0118715303355221241021050443. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791179

174

Rare of Gaucher's Disease Complication of Splenic Multiple Gaucheroma.

Çukadar N, Veziroğlu İE, Kara CS, Karahan OI, Talih T, Bayram F. Çukadar N, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 8;25(14):1199-204. doi: 10.2174/0118715303325860241023063241. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791178 Free PMC article.

175

Improving Renal Protection in Chronic Kidney Disease Associated with Type 2 Diabetes: The Role of Finerenone.

Nugroho P. Nugroho P. Endocr Metab Immune Disord Drug Targets. 2025 Jan 8;25(14):1133-47. doi: 10.2174/0118715303350851241021105850. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791177 Free PMC article.

176

Neonatal Pain Management: Is There An Endocrinal Response?

Elfarargy MS, Ahmad AR, Elbadry DH. Elfarargy MS, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(11):835-847. doi: 10.2174/0118715303325556241127080237. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791176 Free PMC article. Review.

177

Identification of Programmed Cell Death-related Biomarkers for the Potential Diagnosis and Treatment of Osteoporosis.

Huo Y, Guo M, Li Y, Yao X, Tian Q, Liu T. Huo Y, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(11):864-878. doi: 10.2174/0118715303326112241021061805. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791175 Free PMC article.

178

The Potential Systemic Anti-Inflammatory Effect of Turmeric Dried Extract.

Montanino C, Farinella F, De Felice B, Del Buono A, D'Orta A. Montanino C, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 8;25(14):1191-8. doi: 10.2174/0118715303329562241116045410. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791174 Free PMC article.

179

Berberine Improves Glucose and Lipid Metabolism in Obese Mice Through the Reduction of IRE1/GSK-3β Axis-Mediated Inflammation.

Ding L, Xia J, Wang H, Qian J, Jin X, Yang Y, Xia J, Shang W, Chen M. Ding L, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(11):855-863. doi: 10.2174/0118715303319434241113161606. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791173 Free PMC article.

180

Optimizing Care for Primary Glomerulonephritis: The Role of Thyroid Evaluation.

Demir AN, Karaca C, Kara Z, Sulu C, Sahin S, Durcan E, Dincer MT, Nurcan SE, Sonmez O, Ozkaya HM, Seyahi N, Gonen MS. Demir AN, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(11):905-914. doi: 10.2174/0118715303328436241121114054. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791172 Free PMC article.

181

Beyond the Surface: Tracing the Evolution of Inflammatory Mechanism in Depression through Bibliometric Analysis.

Xu ZY, Zhang T, Gong H, Zheng H, Liu MS, Guo BH, Wang YX, Su WJ. Xu ZY, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(10):789-810. doi: 10.2174/0118715303325541241024060229. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791171 Free PMC article. Review.

182

Protective Effects of Hydrogen Treatment Against High Glucose-Induced Oxidative Stress and Apoptosis via Inhibition of the AGEs/RAGE/NF-κB Signaling Pathway in Skin Cells.

Yu P, Hong N, Wu Q, Zhao Z. Yu P, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 8;25(14):1177-90. doi: 10.2174/0118715303369584241231141001. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791170 Free PMC article.

183

Interlinking the Cross Talk on Branched Chain Amino Acids, Water Soluble Vitamins and Adipokines in the Type 2 Diabetes Mellitus Etiology.

Rai PS, Bhandary YP, Shivarajashankara YM, Akarsha B, Bhandary R, Prajna RH, Namrata KG, Savin CG, Alva P, Katyayani P, Shetty S, Sudhakar TJ. Rai PS, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(10):757-766. doi: 10.2174/0118715303305579241014112730. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791169 Free PMC article. Review.

184

Significance of Serum Magnesium in Parathyroid Hormone Level in Patients with Chronic Kidney Disease.

Wang J, Lin Y, Chen X, Li HY, Tang W, Zhou T. Wang J, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(11):896-904. doi: 10.2174/0118715303311081241022042321. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791168 Free PMC article.

185

Identification of Biomarkers Related to Liquid-Liquid Phase Separation for Ulcerative Colitis Based on Single-Cell and Bulk RNA Transcriptome Sequencing Data.

Lu J, Lu X, Chen B. Lu J, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 8;25(14):1160-76. doi: 10.2174/0118715303355042241208171133. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791167 Free PMC article.

186

Evaluating the Relationship between Cathepsins and Papillary Thyroid Carcinoma: A Mendelian Randomization Study.

Muge L, Xiongsheng X, Ling J, Siyi L, Changwei Z, Zhengde C, Zhuoting C, Zhi Z. Muge L, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(10):811-819. doi: 10.2174/0118715303305715240912172648. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39791166 Free PMC article.

187

Exploring the Impact of Extended Amino Acid Supplementation on Body Composition and Psychopathology in Patients with Eating Disorders Undergoing Psycho-Nutritional Rehabilitation.

Napolillo M, Ragione LD, Iaco G, Mococci T, Sacco R, Marucci S. Napolillo M, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 3. doi: 10.2174/0118715303310253241210080238. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39773035

188

Association of Toll-like Receptor 4 Gene Polymorphisms with Diabetes Type 2 Patients in the Palestinian Population.

Al-Razem F, Iqnaibi EB, Abu Rmeileh RA, Ideis LI. Al-Razem F, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(9):675-681. doi: 10.2174/0118715303301789240826113528. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39773034

189

Research Hotspots and Trends of RNA Research in Diabetic Retinopathy: Insights From Bibliometric Analysis.

Yin D, Luo X, Wei M, Tang Y, Jiang Y, Wang C, Li A, Guo J, Gong Y. Yin D, et al. Endocr Metab Immune Disord Drug Targets. 2025 Jan 3;25(13):1045-59. doi: 10.2174/0118715303358069241213151650. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39773033 Free PMC article.

190

PF4 Silencing Promotes Trophoblast Cell Proliferation, Migration, Invasion and EMT by Regulating SOCS3/STAT3 Signaling Pathway.

Cao H, Li R, Ling L, Ni G. Cao H, et al. Endocr Metab Immune Disord Drug Targets. 2024 Dec 17. doi: 10.2174/0118715303299470240723060939. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 39694960

191

The Molecular Determinants of Erythrocyte Removal Impact the Development of Metabolic Dysfunction-Associated Steatohepatitis.

Charalampos P. Charalampos P. Endocr Metab Immune Disord Drug Targets. 2024 Dec 9;25(13):1031-4. doi: 10.2174/0118715303362972241121062515. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 39660491 Free PMC article.

192

Acute suppurative thyroiditis caused by Gemella Morbillorum: a case report.

Brunetti A, Cipri C, Sartor A, Bergamin-Bracale AM, Manso J, Vescini F. Brunetti A, et al. Endocr Metab Immune Disord Drug Targets. 2024 Oct 24;25(13):1110-5. doi: 10.2174/0118715303347962241018091143. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 39648292 Free PMC article.

193

Asymptomatic Hypocalcemia Related to Denosumab Administration in Bone-Metastatic Patient Affected by Colorectal Cancer: A Case Report.

Corsello A, Torino F, Rosa A, D'Addario D, Cannarsa C, Paragliola RM. Corsello A, et al. Endocr Metab Immune Disord Drug Targets. 2024 Dec 5;25(13):1116-21. doi: 10.2174/0118715303347379241107095529. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 39639476 Free PMC article.

194

Comprehensive Analysis of circRNA and mRNA Revealing Potential Mechanism Underlying Neuroinflammation in BV2 Cells.

Jiang S, Zhang X, Xu J, Liu Y, Chen W, Zhang J, Wang J. Jiang S, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(9):682-694. doi: 10.2174/0118715303321231240905073202. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39620326

195

Ketogenic Diet and Endocrine and Metabolic Diseases: A Bibliometric Study and Visualization Analysis.

Zhang X, Jiang Y, Cai T, Huang Z, Wu Y, Zhang J. Zhang X, et al. Endocr Metab Immune Disord Drug Targets. 2024 Oct 28;25(8):648-64. doi: 10.2174/0118715303317289240820114329. Online ahead of print. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 39473256 Free PMC article.

196

Safety Profile of Statins for Post-Marketing Adverse Cardiovascular Events: A Real-World Pharmacovigilance Analysis.

Li J, Gong J, Liu Z, Liu Y, He A, Wang Z. Li J, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(9):746-756. doi: 10.2174/0118715303324204240905111835. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39473255 Free PMC article.

197

Tanshinone IIA Regulates NRF2/NLRP3 Signal Pathway to Restrain Oxidative Stress and Inflammation in Uric Acid-Induced HK-2 Fibrotic Models.

Zhang W, Feng J, Liu R, Xiang T, Wu X. Zhang W, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(9):721-731. doi: 10.2174/0118715303315786240926075342. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39473254 Free PMC article.

198

Effects of Ethanol Extract from Senna Leaf (EESL) on Inflammation and Oxidative Stress in Mice: A Non-targeted Metabolomic Study.

Huang X, Sun W, Sun C, Tan J, Wu L, Yang F. Huang X, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(9):695-709. doi: 10.2174/0118715303325372241014152811. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39449343 Free PMC article.

199

Revealing Fibrosis Genes as Biomarkers of Ulcerative Colitis: A Bioinformatics Study Based on ScRNA and Bulk RNA Datasets.

Wang Y, Liu L, Wang W. Wang Y, et al. Endocr Metab Immune Disord Drug Targets. 2025;25(9):710-720. doi: 10.2174/0118715303332155240912050838. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39428941 Free PMC article.

200

Mediterranean and Japanese Diets as Promoters of Wellbeing and Longevity: Commonalities and Differences.

Santacroce L, Topi S, Santa K, Nagaoka I, Jirillo E, Kumazawa Y. Santacroce L, et al. Endocr Metab Immune Disord Drug Targets. 2024;24(15):1709-1710. doi: 10.2174/187153032415240725162847. Endocr Metab Immune Disord Drug Targets. 2024. PMID: 39428579 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,898 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,898 results

Results by year